National Institute of Allergy and Infectious Diseases; Closed Meeting, 81832-81833 [2015-32911]
Download as PDF
<![CDATA[
81832
Federal Register / Vol. 80, No. 251 / Thursday, December 31, 2015 / Notices
TABLE A.12–1.3—ESTIMATE OF RESPONDENT BURDEN, GENERATION 3 COHORT, NOS AND OMNI GROUP 2 COHORT—
Continued
[Annualized]
Number of
respondents
Type of respondent
Number of
responses per
respondent
Average time
per response
(hours per
year)
Total annual
burden hour
2. Home or nursing home visit .................................................................
C. POST-EXAM:
eFHS Mobile Technology for Collection of CVD Risks ............................
D. ANNUAL FOLLOW-UP:
1. Records Request ..................................................................................
2. Health Status Update ...........................................................................
35
1
60/60
35
1,100
18
9/60
2,970
1,200
1,400
1
1
15/60
15/60
300
350
Sub-Total: Participant Components ..................................................
* 2,850
........................
........................
6,830
II. NON-PARTICIPANT COMPONENTS—ANNUAL FOLLOW-UP
A. INFORMANT CONTACTS ..........................................................................
B. RECORD REQUEST ..................................................................................
180
1,155
1
1
10/60
15/60
30
289
Sub-Total: Non-Participant Components ..................................................
1,335
........................
........................
319
Total: Participant And Non-Participant Components ........................
4,185
........................
........................
7,157
* Number of participants as reflected in Rows I.A.1 and I.D.2 above.
Dated: December 22, 2015.
Valery Gheen,
NHLBI Project Clearance Liaison, National
Institutes of Health.
Place: Intramural Research Program,
National Institute on Drug Abuse, NIH, Johns
Hopkins Bayview Campus, Baltimore, MD
21223.
Contact Person: Joshua Kysiak, Program
Specialist, Biomedical Research Center,
Intramural Research Program, National
Institute on Drug Abuse, NIH, DHHS, 251
Bayview Boulevard, Baltimore, MD 21224,
443–740–2465, kysiakjo@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
[FR Doc. 2015–32940 Filed 12–30–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
tkelley on DSK3SPTVN1PROD with NOTICES
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Board
of Scientific Counselors, NIDA.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute on Drug Abuse,
including consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, NIDA.
Date: February 1–2, 2016.
Closed: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
VerDate Sep<11>2014
16:49 Dec 30, 2015
Jkt 238001
Dated: December 28, 2015.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32939 Filed 12–30–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Tools
for Monitoring and Manipulating RNA
Modifications (R41, R42, R43, R44).
Date: February 18, 2016.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Bethesda, 7301
Waverly Street, Bethesda, MD 20814.
Contact Person: Jagadeesh S. Rao, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4234, MSC 9550, Bethesda, MD 02892,
301–443–9511, jrao@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: December 28, 2015.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32937 Filed 12–30–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\31DEN1.SGM
31DEN1
Federal Register / Vol. 80, No. 251 / Thursday, December 31, 2015 / Notices
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Partnerships for the
Development of Novel Assays to Predict
Vaccine Efficacy.
Date: February 3–4, 2016.
Time: 12:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3G61, 5601 Fishers Lane, Rockville, MD
20892 (Telephone Conference Call).
Contact Person: Brenda Lange-Gustafson,
Ph.D., Scientific Review Officer, NIAID/NIH/
DHHS, Scientific Review Program, 5601
Fishers Lane, Room 3G13, Rockville, MD
20852, 240–669–5047, bgustafson@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: December 23, 2015.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32911 Filed 12–30–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
tkelley on DSK3SPTVN1PROD with NOTICES
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
VerDate Sep<11>2014
16:49 Dec 30, 2015
Jkt 238001
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; Clinical Research on
Mind-Body Interventions.
Date: March 25, 2016.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott, 5701
Marinelli Road, Bethesda, MD 20817.
Contact Person: Hungyi Shau, Ph.D.,
Scientific Review Officer, National Center for
Complementary and Integrative Health,
National Institutes of Health, 6707
Democracy Boulevard, Suite 401, Bethesda,
MD 20892, 301–480–9504, Hungyi.Shau@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: December 24, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32909 Filed 12–30–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the meetings of the
National Advisory Council on Alcohol
Abuse and Alcoholism.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
sessions will be videocast and can be
accessed from the NIH Videocasting and
Podcasting Web site (https://
videocast.nih.gov).
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
81833
Name of Committee: National Advisory
Council on Alcohol Abuse and Alcoholism,
National Cancer Advisory Board, and
National Advisory Council on Drug Abuse
Open: February 11, 2016.
Time: 9:00 a.m. to 1:30 p.m.
Agenda: Presentation of NIAAA, NCI, and
NIDA Director’s Update, Scientific Reports,
and other topics within the scope of the
Collaborative Research on Addiction at NIH
(CRAN).
Place: National Institutes of Health,
Terrace Conference Rooms, 5635 Fishers
Lane, Rockville, MD 20892.
Contact: Abraham P. Bautista, Ph.D.,
Director, Office of Extramural Activities,
National Institute on Alcohol Abuse &
Alcoholism, National Institutes of Health,
5635 Fishers Lane, Room 2085, Rockville,
MD 20852, 301–443–9737, bautista@
mail.nih.gov.
Paulette S. Gray, Ph.D., Director, Division
of Extramural Activities, National Cancer
Institute, National Institutes of Health, 9609
Medical Center Drive, Room 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
dea.nci.nih.gov
Susan Weiss, Ph.D., Director, Division of
Extramural Research, National Institute on
Drug Abuse, National Institutes of Health,
6001 Executive Boulevard, NSC, Room 5274,
301–443–6487, sweiss@nida.nih.gov.
Name of Committee: National Advisory
Council on Alcohol Abuse and Alcoholism.
Closed: February 11, 2016.
Time: 2:15 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Terrace Conference Rooms, 5635 Fishers
Lane, Rockville, MD 20892.
Open: February 12, 2016.
Time: 9:00 a.m. to 2:00 p.m.
Agenda: Presentations and other business
of the Council.
Place: National Institutes of Health,
Terrace Conference Rooms, 5635 Fishers
Lane, Rockville, MD 20892.
Contact Person: Abraham P. Bautista,
Ph.D., Executive Secretary, National Institute
on Alcohol Abuse & Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Room
2085, Rockville, MD 20852, 301–443–9737,
bautista@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.niaaa.nih.gov/AboutNIAAA/
AdvisoryCouncil/Pages/default.aspx, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
E:\FR\FM\31DEN1.SGM
31DEN1
]]>Agencies
[Federal Register Volume 80, Number 251 (Thursday, December 31, 2015)]
[Notices]
[Pages 81832-81833]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32911]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
[[Page 81833]]
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Partnerships for the Development of
Novel Assays to Predict Vaccine Efficacy.
Date: February 3-4, 2016.
Time: 12:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Room 3G61, 5601 Fishers
Lane, Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Brenda Lange-Gustafson, Ph.D., Scientific Review
Officer, NIAID/NIH/DHHS, Scientific Review Program, 5601 Fishers
Lane, Room 3G13, Rockville, MD 20852, 240-669-5047,
bgustafson@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: December 23, 2015.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-32911 Filed 12-30-15; 8:45 am]
BILLING CODE 4140-01-P
